Clinical trial
Phase II/III Clinical Study of R484iv (Ibandronic Acid) for Primary Osteoporosis
NCT00447915 · Chugai Pharmaceutical, Industry · Completed
Key facts
| NCT number | NCT00447915 |
|---|---|
| Title | Phase II/III Clinical Study of R484iv (Ibandronic Acid) for Primary Osteoporosis |
| Official title | Phase II/III Clinical Study of R484iv (Ibandronic Acid) for Primary Osteoporosis - Comparative Study With Sodium Risedronate Hydrate(RIS) With Vertebral Fracture as an Index - |
| Lead sponsor | Chugai Pharmaceutical, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Primary Osteoporosis |
| Intervention type | Dietary Supplement, Drug |
| Interventions | ibandronic acid 0.5mg, RIS placebo, 1.0mg ibandronic acid, ibandronic acid placebo, 2.5mg RIS, Calcium and Vitamine D3 |
| Enrollment | 1,265 |
| Start date | Mar 1, 2007 |
| Primary completion | Aug 1, 2011 |
| Completion | Dec 1, 2011 |
| First posted | Mar 15, 2007 |
| Last update posted | Aug 2, 2012 |
| Countries | Japan |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: